Vaxcyte, Inc.
NasdaqGS:PCVX Stock Report
Vaxcyte Past Earnings Performance
Vaxcyte's earnings have been declining at an average annual rate of -47.2%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-47.2%
Earnings growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -14.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
Sep 06We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate
Aug 24Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?
May 10Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Dec 27We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Sep 12Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation
May 30We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth
Dec 22Vaxcyte appoints new CBO, CMO
Oct 11Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Aug 05Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate
Jul 12Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans
Feb 25Revenue & Expenses Breakdown
How Vaxcyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
NasdaqGS:PCVX Revenue, expenses and earnings (USD Millions)| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|
| 30 Sep 24 | 0 | -508 | 82 | 447 |
| 30 Jun 24 | 0 | -497 | 74 | 428 |
| 31 Mar 24 | 0 | -437 | 67 | 369 |
| 31 Dec 23 | 0 | -402 | 61 | 332 |
| 30 Sep 23 | 0 | -300 | 55 | 280 |
| 30 Jun 23 | 0 | -265 | 50 | 230 |
| 31 Mar 23 | 0 | -245 | 45 | 196 |
| 31 Dec 22 | 0 | -223 | 40 | 169 |
| 30 Sep 22 | 0 | -174 | 35 | 141 |
| 30 Jun 22 | 0 | -143 | 30 | 114 |
| 31 Mar 22 | 0 | -118 | 27 | 93 |
| 31 Dec 21 | 0 | -100 | 25 | 78 |
| 30 Sep 21 | 0 | -92 | 23 | 70 |
| 30 Jun 21 | 0 | -87 | 22 | 66 |
| 31 Mar 21 | 0 | -83 | 19 | 67 |
| 31 Dec 20 | 0 | -89 | 16 | 74 |
| 30 Sep 20 | 0 | -83 | 14 | 72 |
| 30 Jun 20 | 0 | -73 | 11 | 66 |
| 31 Mar 20 | 0 | -64 | 11 | 57 |
| 31 Dec 19 | 0 | -50 | 9 | 46 |
| 31 Dec 18 | 0 | -29 | 5 | 30 |
Quality Earnings: PCVX is currently unprofitable.
Growing Profit Margin: PCVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCVX is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.
Accelerating Growth: Unable to compare PCVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PCVX has a negative Return on Equity (-14.85%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
